Drug Profile

PRS 332

Alternative Names: PRS-332

Latest Information Update: 17 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pieris Pharmaceuticals
Developer Palvella Therapeutics
Class Antineoplastics; Immunotherapies; Lipocalins; Monoclonal antibodies; Recombinant fusion proteins
Mechanism of Action CD223 antigen inhibitors; Programmed cell death-1 ligand-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 Dec 2024 Pieris Pharmaceuticals has merged with Palvella Therapeutics to form Palvella Therapeutics
28 Sep 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
23 Mar 2020 Servier terminates its licencing agreement for PRS 332 due to strategic reasons

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com